Skip to main content
. 2014 Jul 17;9(7):e102572. doi: 10.1371/journal.pone.0102572

Figure 7. A summary of the inhibitory effects (to the LFA-1/ICAM-1 interactions) of (a) lovastatin; and (b) LFA-1 derived peptides.

Figure 7

“*” and “**” denote statistical significance with p<0.05 and p<0.005, respectively, from student t-test. NS: Not Significant. In (a), different concentrations of lovastatin were added to the FRET mixture of Alexa Fluor 488- LFA-1 (100 nM) and Alexa Fluor 555-D1-D2-Fc (100 nM). The inhibition efficiency of lovastatin increased from 69.48±0.77% at 0.2 µM to 90.03±0.06% at 200 µM. This result confirms that this FRET based screening assay is capable of identifying/classifying inhibitors of the LFA-1/ICAM-1 interaction based on inhibition efficiency study. From (b), a comparison of the inhibition efficiencies (to the LFA-1/ICAM-1 interactions) of three LFA-1 derived peptides CD11a237–261, CD11a441–465, and CD11a456–465 indicates that CD11a237–261 exhibits the highest inhibition efficiency while CD11a456–465 the lowest for all the concentrations tested in this study.